| Drug repurposing from the perspective of pharmaceutical companies Y Cha, T Erez, IJ Reynolds, D Kumar, J Ross, G Koytiger, R Kusko, ... British journal of pharmacology 175 (2), 168-180, 2018 | 372 | 2018 |
| General report & recommendations in predictive, preventive and personalised medicine 2012: white paper of the European Association for Predictive, Preventive and Personalised … O Golubnitschaja, V Costigliola, ... EPMA Journal 3, 1-53, 2012 | 271 | 2012 |
| Pharmacogenetics of antipsychotic response in the CATIE trial: a candidate gene analysis AC Need, RSE Keefe, D Ge, I Grossman, S Dickson, JP McEvoy, ... European Journal of Human Genetics 17 (7), 946-957, 2009 | 126 | 2009 |
| The sigma-1 receptor mediates the beneficial effects of pridopidine in a mouse model of Huntington disease D Ryskamp, J Wu, M Geva, R Kusko, I Grossman, M Hayden, ... Neurobiology of disease 97, 46-59, 2017 | 123 | 2017 |
| Laquinimod arrests experimental autoimmune encephalomyelitis by activating the aryl hydrocarbon receptor J Kaye, V Piryatinsky, T Birnberg, T Hingaly, E Raymond, R Kashi, ... Proceedings of the National Academy of Sciences 113 (41), E6145-E6152, 2016 | 123 | 2016 |
| Pridopidine activates neuroprotective pathways impaired in Huntington Disease M Geva, R Kusko, H Soares, KD Fowler, T Birnberg, S Barash, ... Human molecular genetics 25 (18), 3975-3987, 2016 | 105 | 2016 |
| Pharmacogenetics of glatiramer acetate therapy for multiple sclerosis reveals drug-response markers I Grossman, N Avidan, C Singer, D Goldstaub, L Hayardeny, E Eyal, ... Pharmacogenetics and genomics 17 (8), 657-666, 2007 | 93 | 2007 |
| Testing for cytochrome P450 polymorphisms in adults with non-psychotic depression treated with selective serotonin reuptake inhibitors (SSRIs). DB Matchar, ME Thakur, I Grossman, DC McCrory, LA Orlando, ... Evidence report/technology assessment, 1-77, 2007 | 80 | 2007 |
| Characterization of the poly-T variant in the TOMM40 gene in diverse populations C Linnertz, AM Saunders, MW Lutz, DM Crenshaw, I Grossman, DK Burns, ... PloS one 7 (2), e30994, 2012 | 79 | 2012 |
| Using genetics to enable studies on the prevention of Alzheimer's disease DG Crenshaw, WK Gottschalk, MW Lutz, I Grossman, AM Saunders, ... Clinical Pharmacology & Therapeutics 93 (2), 177-185, 2013 | 76 | 2013 |
| TOMM40 and APOE: Requirements for replication studies of association with age of disease onset and enrichment of a clinical trial AD Roses, MW Lutz, DG Crenshaw, I Grossman, AM Saunders, ... Alzheimer's & Dementia 9 (2), 132-136, 2013 | 72 | 2013 |
| Global pharmacogenetics: genetic substructure of Eurasian populations and its effect on variants of drug-metabolizing enzymes O Makeeva, V Stepanov, V Puzyrev, DB Goldstein, I Grossman Future Medicine Ltd 9 (7), 847-868, 2008 | 70 | 2008 |
| Dopamine D2 receptor gene variants and response to rasagiline in early Parkinson’s disease: a pharmacogenetic study M Masellis, S Collinson, N Freeman, M Tampakeras, J Levy, A Tchelet, ... Brain 139 (7), 2050-2062, 2016 | 67 | 2016 |
| Review of evidence for genetic testing for CYP450 polymorphisms in management of patients with nonpsychotic depression with selective serotonin reuptake inhibitors M Thakur, I Grossman, DC McCrory, LA Orlando, DC Steffens, KE Cline, ... Genetics in Medicine 9 (12), 826-835, 2007 | 59 | 2007 |
| Genetic determinants of variable metabolism have little impact on the clinical use of leading antipsychotics in the CATIE study I Grossman, PF Sullivan, N Walley, Y Liu, JR Dawson, C Gumbs, ... Genetics in medicine 10 (10), 720-729, 2008 | 52 | 2008 |
| Routine pharmacogenetic testing in clinical practice: dream or reality? I Grossman Future Medicine Ltd 8 (10), 1449-1459, 2007 | 52 | 2007 |
| Alzheimer’s disease: diagnostics, prognostics and the road to prevention I Grossman, MW Lutz, DG Crenshaw, AM Saunders, DK Burns, AD Roses EPMA Journal 1, 293-303, 2010 | 51 | 2010 |
| Early pridopidine treatment improves behavioral and transcriptional deficits in YAC128 Huntington disease mice M Garcia-Miralles, M Geva, JY Tan, NABM Yusof, Y Cha, R Kusko, LJ Tan, ... JCI insight 2 (23), 2017 | 44 | 2017 |
| Bio-markers of disease activity and response to therapy in multiple sclerosis A Miller, L Glass-Marmor, M Abraham, I Grossman, S Shapiro, Y Galboiz Clinical neurology and neurosurgery 106 (3), 249-254, 2004 | 41 | 2004 |
| ADME pharmacogenetics: current practices and future outlook I Grossman Expert opinion on drug metabolism & toxicology 5 (5), 449-462, 2009 | 37 | 2009 |
Michael HaydenKillam Professor, University of British ColumbiaVerified email at cmmt.ubc.ca
